As GSE uncertainty grows, Figure CEO says his company is ready to fill the void

Date:

Share post:


“Figure Connect coming in at 65% when we only launched that platform two years ago reflects that the market is really interested in what we’re offering there,” he said. “There’s a lot of pull into that marketplace.”

The Kiavi deal adds the business purpose lending market, where roughly 25% of US housing stock is investor-owned, and Kiavi holds approximately 10% market share while the next largest competitor sits at around 2%, according to Tannenbaum.

The combination of Figure and Kiavi opens new doors for both companies. Figure’s home equity product is capped at around 85% loan-to-value, while Kiavi’s technology allows loans to go above 100% of the current home price based on a post-renovation valuation, creating a valuable product for home improvement borrowers.

“Forty percent of home equity is home improvement,” he said. “Think about how many people would be interested in borrowing against the pro forma — borrowing 100% of today’s value or more for renovation. Kiavi is not doing the HELOC, but we have the HELOC technology, and we can add their post-renovation valuation. That’s a really valuable connection point.”

What brokers need to know

Tannenbaum said the $35 trillion in available home equity, a Federal Reserve figure tracked quarterly, is where the action is for mortgage partners right now, and brokers without a home equity strategy are leaving business on the table.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Maybe Mortgage Rates Did Like the Fed Rate Hike After All

Mortgage rates are lower today after the market finally digested the first Fed rate hike since 2023.The...

SEC Publishes Innovation Exemption For Tokenized Stocks

As expected, the Securities and Exchange Commission (SEC) has published its “Innovation Exemption” for tokenized or digital...

Greg Abel Exited a Consumer Brand Warren Buffett Backed for 6 Straight Quarters. Here’s Why That Was the Wrong Move.

Greg Abel has the unenviable task of succeeding legendary investor Warren Buffett as CEO of Berkshire Hathaway...

BetterLife Pharma closes $100M public offering for drug trials

BetterLife Pharma closes $100M public offering for drug trials